Mohamed Sikkander Abdul Razak: A New Strategy to Reprogram Cancer Cells Instead of Killing Them
Mohamed Sikkander Abdul Razak, Professor at GKM College of Engineering Technology, shared a post on LinkedIn:
“Scientists at KAIST have identified three genetic switches – MYB, HDAC2, and FOXA2 – that keep cancer cells, specifically colon cancer cells, in a malignant state.
By inhibiting these genes, they’ve successfully reprogrammed cancer cells to behave like normal, healthy cells.
This breakthrough could lead to a new approach in cancer treatment, focusing on reprogramming rather than killing cancer cells.
Some key points about this research:
- MYB: Often overactive in colon and blood cancers, promoting growth and preventing cell maturation.
- HDAC2: Helps cancer cells survive by shutting down protective genes.
- FOXA2: Plays complex roles in cell development and cancer growth.
The researchers used a computational model called BENEIN to identify these genetic switches and achieved promising results in lab and animal studies.
This research could lead to:
- Targeted therapies: Developing treatments that reprogram cancer cells to behave normally, reducing harm to healthy cells.
- Personalized medicine: Identifying specific genetic switches in individual patients’ cancers to tailor treatments.
- Combination therapies: Using reprogramming approaches alongside existing treatments like chemotherapy.
- Cancer prevention: Potentially preventing cancer progression in high-risk individuals.
The BENEIN model could also be applied to other cancer types, making it a valuable tool.
Some challenges:
- Specificity: Ensuring treatments target cancer cells only, avoiding off-target effects.
- Delivery: Effectively delivering therapies to all cancer cells, especially in solid tumors.
- Resistance: Cancer cells might develop resistance to reprogramming.
- Long-term efficacy: Ensuring reprogrammed cells remain healthy long-term.
- Complexity: Cancer involves multiple pathways; targeting three switches might not be enough.
Translating lab findings to human treatments will require careful clinical trials.”
Stay updated with Hemostasis Today.
-
Jun 15, 2026, 10:49Aurelio Maggio: How Is The Treatment Landscape Of Thrombotic Thrombocytopenic Purpura Evolving?
-
Jun 15, 2026, 10:49Marek Mráz: A Landmark EHA 2026 for Our Lab
-
Jun 15, 2026, 10:32Magnus Ek: Operational Excellence in Delivering Seamless Access for 17,000 Delegates at EHA 2026 Congress
-
Jun 15, 2026, 10:15Carol Bewick: Why the Global Community Makes EHA 2026 Unforgettable
-
Jun 15, 2026, 10:07Habib Bennaceur: Driving Haemoglobinopathies Progress Across Multiple Clinical Programmes At EHA 2026
-
Jun 14, 2026, 22:49Cihan Ay: From First Oral Presentation to Pro and Con Debate – A 20-Year EHA Journey
-
Jun 14, 2026, 19:54Tareq Abadl: What Happens If You Transfuse the Wrong Blood Group?
-
Jun 14, 2026, 19:46Amber Yates: Stretching Scientific Muscles in Areas of Hematology – Day 2 at EHA 2026
-
Jun 14, 2026, 19:41Peter Loffelhardt: Thousands of People Coming in – Second Day at EHA 2026